First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962)
- PMID: 27007010
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962)
Publication types
- "V体育安卓版" Actions
MeSH terms
- "VSports在线直播" Actions
- "VSports在线直播" Actions
- "VSports在线直播" Actions
- "V体育ios版" Actions
- V体育官网 - Actions
- VSports在线直播 - Actions
- "VSports app下载" Actions
- VSports注册入口 - Actions
- "V体育安卓版" Actions
"V体育官网" Substances
- Actions (V体育ios版)
- Actions (V体育2025版)